Investigating blood markers in meningioma patients undergoing radiotherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to explore the role of plasma extracellular vesicles (EVs) in patients with meningiomas who are receiving radiotherapy. A total of 60 patients with confirmed meningiomas and indications for radiotherapy will have blood samples collected before, during, and after treatment, as well as during follow-up. The study will analyze these samples to identify potential biomarkers for tumor progression and to develop DNA methylation profiles for better risk stratification and clinical management of meningioma patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* confirmed meningioma (histologically or MRI/DOTATOC-PET CT)
* macroscopic tumor in MRI (either as definitive RT, or following subtotal resection or relapse)
* indication for radiotherapy
* completed wound healing after surgical intervention)
* Alter ≥ 18 Jahre
* Karnofsky Performance Score ≥ 60%
* written informed consent
* ability of subject to understand character and individual consequences of the trial
* adequate contraception for women of childbearing potential

Exclusion Criteria:

* previous or known tumor diseases \< 5 years ago
* previous (cerebral) radiotherapy
* simultaneous chemo/immunotherapy
* evidence that the patient cannot adhere to the study protocol (e.g., non-compliance)
* the refusal of patients to participate in the study
* participation in another clinical study or observation period in a competing trial

Where it's running

• University Hospital of Heidelberg, Radiation Oncology
  Heidelberg, Germany Recruiting

Study contacts

• Study coordinator: Max Deng, MD
• Email: maximilian.deng@med.uni-heidelberg.de
• Phone: +496221 56

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combination therapy with IN10018 and dalpiciclib for progressive meningioma

  This phase 1 study tests whether taking IN10018 with dalpiciclib is safe and tolerable in adults with growing meningiomas to see if the combo can help control the tumor.

  Recruiting Phase 1 Capital Medical University · Beijing, Beijing Municipality and 1 other locations · NCT07652762

• JZP3507 (ONC206) for recurrent Grade 2/3 meningioma

  A pill-based therapy (JZP3507) is being tested to see if it can help adults with recurrent grade 2 or 3 meningioma who have not benefited from standard treatments.

  Recruiting at 6 sites Phase 2 Jazz Pharmaceuticals · San Francisco, California and 7 other locations · NCT07533942

• Panitumumab-IRDye800 for guiding brain tumor surgery

  A tiny dose of panitumumab-IRDye800 is tested to see if it helps visualize brain tumors during surgery in adults.

  Recruiting Early Phase 1 Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT07493447

• Zanzalintinib for recurrent or progressive meningioma

  This trial tests whether zanzalintinib can help people whose meningioma has come back or kept growing after standard treatments.

  Recruiting at 20 sites Phase 2 Exelixis · Birmingham, Alabama and 19 other locations · NCT07428616

• Meningioma: How social factors and personal risks relate to health outcomes

  This study tests whether social and personal risk factors help explain differences in health outcomes for adults with meningioma.

  Recruiting University of California, San Francisco · San Francisco, California · NCT07418775

• Skin closure after brain tumor surgery: running absorbable versus interrupted non-absorbable sutures

  This will test whether absorbable running intradermal sutures or non-absorbable interrupted transdermal sutures produce better wound healing after craniotomy in adults with supratentorial brain tumors.

  Recruiting Medical University of Warsaw · Warsaw, Masovian Voivodeship · NCT07413796

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.